Skip to content
TriangleGet started
← Aggressive B-Cell Non-Hodgkin Lymphoma

HEALTH PROFESSIONAL · SOURCE READING

Treatment Options for Aggressive, Recurrent B-Cell Non-Hodgkin Lymphoma

Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.

Context: Treatment of Aggressive, Recurrent B-Cell Non-Hodgkin Lymphoma

In a retrospective review of multiple international trials, 636 patients were identified as having refractory diffuse large B-cell lymphoma (DLBCL), which was defined as progression or stable disease during or just at completion of full-course chemotherapy or relapse within 1 year after autologous stem cell transplant (SCT).[1] With subsequent therapy, the objective response rate was 26%, complete response rate was 7%, median overall survival (OS) was 6.3 months, and only 20% of patients were alive at 2 years. Even with reinduction chemotherapy with planned autologous SCT, outcomes remain poor.[2]

Source links and citations

Treatment options for aggressive, recurrent B-cell non-Hodgkin lymphoma include the following:

Chimeric antigen receptor (CAR) T-cell therapy for primary refractory disease or relapse within 1 year (or for relapse after autologous SCT).

Source links and citations

Chimeric antigen receptor (CAR) T-cell therapy for primary refractory disease or relapse within 1 year (or for relapse after autologous SCT).

Axicabtagene ciloleucel (axi-cel).

Chimeric antigen receptor (CAR) T-cell therapy for primary refractory disease or relapse within 1 year (or for relapse after autologous SCT).

Lisocabtagene maraleucel (liso-cel).

Bone marrow transplant (BMT)/SCT consolidation.

Source links and citations

Tafasitamab plus lenalidomide.

Source links and citations

Bispecific T-cell engagers.

Source links and citations

Bispecific T-cell engagers.

Epcoritamab.

Source links and citations

Bispecific T-cell engagers.

Glofitamab.

Source links and citations

Polatuzumab vedotin plus rituximab and bendamustine.

Source links and citations

Loncastuximab tesirine.

Source links and citations

Rituximab plus lenalidomide.

Source links and citations

Palliative radiation therapy.

Source links and citations

Continue within this section

CAR T-cell therapy for primary refractory disease or relapse within 1 year (or relapse after autologous SCT) →BMT or SCT consolidation →CAR T-cell therapy for relapse after autologous SCT →Tafasitamab plus lenalidomide →Bispecific T-cell engagers →Polatuzumab vedotin plus rituximab and bendamustine →Loncastuximab tesirine →Rituximab plus lenalidomide →Palliative radiation therapy →

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Independent clinical review pending · Not medical advice